Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 294

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 294
---
 Florida corporation in August 2021 for the purpose of pursuing the development and commercialization of Telomir-1
in the United States in human applications. We were originally incorporated under the name “Metallo Therapies Inc.” and changed
our name to “Telomir Pharmaceuticals, Inc.” in October 2022.

Our
corporate headquarters is a virtual office and is located at 100 SE 2nd St., Suite 2000 #1009 Miami, Florida 33131. Our
telephone number is (786) 396-6723.

Our
website address is www.telomirpharma.com. The information contained on, or that can be accessed through, our website is deemed not to
be incorporated in this Annual Report or to be part of this Annual Report. You should not consider the information contained on our website
to be part of this Annual Report

ITEM
1A. Risk Factors

RISK
FACTORS

Investing
in shares of our common stock is very speculative and involves a high degree of risk. You should carefully consider the risks
and uncertainties described below, the section of this Annual Report entitled “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” and our financial statements and related notes included elsewhere in this Annual Report. The
risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or
that we currently believe are not material, may also become important factors that affect us. If any of the following risks occur, our
business, operating results and prospects could be materially harmed. In that event, the price of our common stock could decline, and
you could lose part or all of your investment.

Summary
Risk Factors

Our
business is subject to numerous risks and uncertainties that you should consider before investing in our company. You should carefully
consider all of the risks described more fully in the section titled “Risk Factors” in this Annual Report on page 19,
before deciding to invest in our common stock. If any of these risks actually occurs, our business, financial condition and results of
operations would likely be materially adversely affected. 

19

Important
factors that could cause actual results or events to differ materially, but are not limited to, the following:

Risks
Related to Our Intellectual Property

We
depend on rights to Telomir-1 that are or will be licensed to us.

We
may not be able to adequately protect our product candidates or